QDEL1 Stock Chart & Stats
$570.28
$0.00(0.00%)
At close: 4:00 PM EDT
$570.28
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$570.28 - $570.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$19.60B
Enterprise Value$3.74K
Total Cash (Recent Filing)$140.40M
Total Debt (Recent Filing)$2.87B
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.85
Shares Outstanding68,190,990
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$238.22Price Target Upside-58.23% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue DiversificationA high non‑respiratory mix (>88% of Q1 revenue) reduces reliance on volatile respiratory seasonality and supports steadier consumables demand tied to installed instruments. That diversification improves durable revenue visibility and stabilizes recurring pull‑through over multiple quarters.
Product & M&A ExpansionThe Lex acquisition and new test launches (troponin, VITROS 450 rollout) expand the company’s addressable market and create new instrument placements that drive long‑term recurring assay and reagent revenue. This builds multi‑year growth drivers beyond legacy respiratory cycles.
Experienced Financial LeadershipHiring an experienced med‑tech CFO and an orderly transition with the prior CFO advising strengthens capital allocation, execution on margin and cash‑generation targets, and investor communication—key capabilities for sustaining a medium‑term turnaround in profitability.
Bears Say
Elevated LeverageHigh leverage reduces financial flexibility and raises refinancing and interest risk, limiting the company’s ability to fund organic growth or absorb revenue shocks. Even planned deleveraging to ~3.25–3.5x leaves limited headroom and increases vulnerability over the next several quarters.
Weak Cash GenerationNegative free cash flow and deteriorated operating cash flow curtail self‑funding for R&D, capex, and working capital. The company has drawn on revolver capacity, implying ongoing reliance on external financing or sustained cost cuts that could constrain strategic investments.
Profitability & Revenue PressureA swing to sizable losses and declining revenue signals structural headwinds from adverse product mix and weaker demand. Prolonged weak profitability erodes returns, may necessitate persistent cost actions, and raises execution risk for restoring sustainable margins.
QuidelOrtho News
QDEL1 FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $570.28 and its highest was $570.28 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $19.60B.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on May 05, 2026. The company reported -$0.694 earnings per share for the quarter, missing the consensus estimate of $6.193 by -$6.887.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is -0.85.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,190,990 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of -$0.694 in its last earnings report, missing expectations of $6.193. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in MX:QDEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$238.22 (-58.23% Downside)
$238.22 (-58.23% Downside)
Blogger Sentiment
Bullish
MX:QDEL1 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.89%
Trailing 12-Months
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL1 Company Deck
QDEL1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: near-term headwinds were significant (a ~30% weaker respiratory season, an 8% decline in labs revenue, quarter-level margin and cash flow pressure, and China distributor pauses), but management emphasized strategic progress—completion of the Lex acquisition, new product launches (troponin, VITROS 450), cost actions, and a full-year plan targeting a 23% adjusted EBITDA margin and positive free cash flow of $100M–$120M. Given the company’s proactive mitigation steps, clear product and pipeline catalysts, and multi-pronged margin initiatives versus the material but largely contextual short-term revenue and cash setbacks, the tone is balanced between caution on near-term execution risks and optimism on medium-term recovery and margin improvement.View all MX:QDEL1 earnings summariesQDEL1 Stock 12 Month Forecast
Average Price Target
$238.22
▼(-58.23% Downside)